Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

SML0038

Sigma-Aldrich

Fluvastatin sodium hydrate

≥98% (HPLC)

Sinonimo/i:

(±)-(3R*,5S*,6E)-7-[3-(4-Fluorophenyl)-1-(1-methyethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 MG
96,70 €
50 MG
387,00 €

96,70 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Scegli un formato

Cambia visualizzazione
10 MG
96,70 €
50 MG
387,00 €

About This Item

Formula empirica (notazione di Hill):
C24H25FNO4 · Na · xH2O
Numero CAS:
Peso molecolare:
433.45 (anhydrous basis)
Numero MDL:
Codice UNSPSC:
12352204
ID PubChem:
NACRES:
NA.77

96,70 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

powder

Condizioni di stoccaggio

desiccated

Colore

white to tan

Solubilità

H2O: ≥9 mg/mL

Ideatore

Novartis

Temperatura di conservazione

2-8°C

Stringa SMILE

O.[Na+].CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c(-c2ccc(F)cc2)c3ccccc13

InChI

1S/C24H26FNO4.Na.H2O/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);;1H2/q;+1;/p-1/b12-11+;;/t18-,19-;;/m1../s1
KKEMYLLTGGQWCE-PMRANXHDSA-M

Applicazioni

Fluvastatin sodium hydrate has been used:
  • to examine its effect on β -glucan-induced training on immunity[1]
  • to investigate the effect of statins on the number of uncoupling protein 1 (UCP1)+ cells[2]
  • to determine its effect on insulin degrading enzyme (IDE) secretion from astrocytes[3]
  • to treat and study its effect on human umbilical vein endothelial cells (HUVECs) in vitro[4]

Fluvastatin sodium hydrate has been used:
  • to test its anti-hepatitis C virus (HCV) activity[5]
  • as a cholesterol inhibitor[6]
  • to study its effects on β-glucan-induced monocyte immune training[1]

Azioni biochim/fisiol

Fluvastatin has antifungal activity.[7]
Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Caratteristiche e vantaggi

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Lovastatin Lovastatin, CAS 75330-75-5, is an anti-hypercholesterolemic agent that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

Sigma-Aldrich

438185

Lovastatin

Mevastatin ≥98% (HPLC), powder or crystals

Sigma-Aldrich

M2537

Mevastatin

Cefaclor

Sigma-Aldrich

C6895

Cefaclor

Simvastatin analytical standard

Supelco

38956

Simvastatin

Piroxicam ≥98% (TLC)

Sigma-Aldrich

P5654

Piroxicam

Avasimibe: a novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles
Hu L, et al.
Antiviral Research, 148, 5-14 (2017)
Kazuho Sakamoto et al.
The Journal of pharmacology and experimental therapeutics, 338(1), 62-69 (2011-04-07)
HMG-CoA reductase inhibitor statins are used for the treatment of hypercholesterolemia. However, statins have adverse effects on skeletal muscles with unknown mechanism. We have reported previously that fluvastatin induced vacuolation and cell death in rat skeletal myofibers by depleting geranylgeranylpyrophosphate
Mojca Lunder et al.
Atherosclerosis, 215(2), 446-451 (2011-02-09)
Early arterial wall changes are already present in the apparently healthy, middle-aged population and continuously progress with age. The aim of our study was to investigate whether 30 days low-dose fluvastatin treatment could improve and reverse these arterial changes that
Current Cardiovascular Drugs (2005)
Metabolic induction of trained immunity through the mevalonate pathway
Bekkering S, et al.
Cell, 172(1-2), 135-146 (2018)

Articoli

Discover Bioactive Small Molecules for Lipid Signaling Research

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.